Skip to main content

Xavier Montalban Gairín

I am Chair of the Department of Neurology since 2012 and director of the Multiple Sclerosis Center of Catalonia (Cemcat) since 2007 at the Vall d'Hebron University Hospital. I am the head of the Neuroimmunology Research Group at Vall d’Hebron Research Institute (VHIR) since 1995. I am Professor of Neurology at the Autonomous University of Barcelona (UAB) since 2006 and at the University of Vic - Central University of Catalonia (UVic-UCC) since 2021.

Institutions of which they are part

Head of group
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Neurology
General Hospital
Director
Multiple Sclerosis Centre of Catalonia

Xavier Montalban Gairín

Institutions of which they are part

Head of group
Clinical Neuroimmunology
Vall Hebron Institut de Recerca
Neurology
General Hospital
Director
Multiple Sclerosis Centre of Catalonia

I am Chair of the Department of Neurology since 2012 and director of the Multiple Sclerosis Center of Catalonia (Cemcat) since 2007 at the Vall d'Hebron University Hospital. I am the head of the Neuroimmunology Research Group at Vall d’Hebron Research Institute (VHIR) since 1995. I am Professor of Neurology at the Autonomous University of Barcelona (UAB) since 2006 and at the University of Vic - Central University of Catalonia (UVic-UCC) since 2021.

I obtained my MD (1983) and PhD (1990) from UAB, and I completed my postgraduate fellowship at St. Thomas' Hospital and the National Hospital for Neurology and Neurosurgery in London. I obtained a Diploma in Comprehensive of Healthcare Institutions Management from ESADE (2005).

In addition to the positions I currently hold, between 2017 and 2020 I served as Professor of Medicine and Director of the Division of Neurology at the University of Toronto and as Director of the MS Center at St Michael's Hospital in the same city.

Since January 2023 I am the chair of the International Advisory Committee on Clinical Trials in Multiple Sclerosis sponsored by ECTRIMS and the National Multiple Sclerosis Society (NMSS), one of the most influential Committee in MS worldwide.

Regarding other leadership roles I am past President (2014-2016) and current Honorary Member of the Council of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). I’m also Board Member of the European Charcot Foundation, as well as serving on numerous local, national and international boards and committees.

My scientific production acrues over 800 scientific papers published in peer-reviewed journals, amounting? more than 52,000 citations and a Scopus H-Index of 101. Over the last consecutive five years I have ranked among the Clarivate most cited researchers.

I have been the Principal Investigator (PI) or Collaborator in more than 35 competitive Projects and have participated as PI in more than 150 clinical trials.

Of Note, I am the recipient of the 2022 John Dystel Prize for MS Research, awarded jointly by the National Multiple Sclerosis Society (NMSS) and the American Academy of Neurology (AAN). I’m the winner of the 2023 Charcot Award granted by the Multiple Sclerosis International Federation (MSIF), which recognises a lifetime of achievement in outstanding research into understanding and treating MS.

Projects

Immunogenicity: assesing the clinical relevance and risk minimization of antibodies to biopharmaceuticals. IMI Grant Agreement nº 115303

IP: Manuel Comabella Lopez
Collaborators: Carmen Tur Gomez, Xavier Montalban Gairín, Nicolás Miguel Fissolo
Funding agency: The Innovative Medicines Initiative
Funding: 464328
Reference: ABIRISK_IMI2010
Duration: 01/03/2012 - 27/02/2018

Search for new treatments for multiple sclerosis by means of massive screening of chemical compounds based on gene expressión through the use of connectivity maps

IP: Xavier Montalban Gairín
Collaborators: Miriam Izquierdo Sans
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 96000
Reference: JCI-2011-11491
Duration: 08/06/2012 - 07/06/2015

Ministerio de Ciencia

Búsqueda de biomarcadores en esclerosis múltiple (EM) basada en perfiles de expresión génica mediante ultrasecuenciación

IP: Xavier Montalban Gairín
Collaborators: Sunny Malhotra Sareen
Funding agency: Instituto de Salud Carlos III
Funding: 185130
Reference: PI10/02099
Duration: 01/01/2011 - 31/03/2015

Función de las semaforinas 3A y 7A, moléculas de guía axonal, en la neurodegeneración y la regulación de la respuesta inmunitaria en la encefalomielitis autoinmune experimental

IP: Xavier Montalban Gairín
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 54000
Reference: FI10/00456
Duration: 15/09/2010 - 14/09/2014

Related news

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.

The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.

Related professionals

Adria Aterido Ballonga

Adria Aterido Ballonga

Postdoctoral researcher
Rheumatology
Read more
Mònica Pons Delgado

Mònica Pons Delgado

Predoctoral researcher
Liver Diseases
Read more
Elena Granell  Pallares

Elena Granell Pallares

Administration and Management
Rheumatology
Read more
David Gurwitz

David Gurwitz

Senior researcher
Systemic Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.